Interventions To Combat Epidemic Of Obesity And Obesity-Related Diseases Will Be Tailored To 4 Different Ethnic Populations; Genetic Predispositions Also Will Be Tested.
WHAT
The Academic Medicine Development Company (AMDeC), a consortium of 33 of New York State's medical schools, academic health centers and major medical research institutions, will announce a major 5-year study to test interventions designed to delay or prevent the onset of Type II Diabetes in children. The study will involve 1,000 students recruited from public schools in Manhattan, Brooklyn and Nassau County.
The study is made possible with a $5 million grant from the Starr Foundation.
By 2025, 50 million people, nearly 1 in 6 Americans, will suffer from diabetes. Within the next 20 years diabetes threatens to overtake cardiovascular disease as the number one killer in the U.S. As children have become increasingly overweight, Type II Diabetes, once called 'Adult-Onset Diabetes,' has become a pediatric affliction.
The Obesity and Type II Diabetes Intervention Program will be conducted under the direction of two Principal Investigators, Dr. Michael Rosenbaum, Associate Professor of Clinical Pediatrics and Medicine at Columbia University's College of Physicians & Surgeons, and Dr. Steven Shelov, Chairman of the Department of Pediatrics and Vice President of Maimonides Infants and Children's Hospital of Brooklyn.
WHEN
Tuesday, April 4, 2006
10:00 AM
WHERE
The Charles B. Rangel Community Health Center
534 West 135th Street (between Amsterdam Avenue and Broadway)
Manhattan
WHO
-- Maurice R. "Hank" Greenberg
Chairman, The Starr Foundation
-- Dr. Herbert Pardes
President & CEO, New York-Presbyterian Hospital
-- Dr. Michael Rosenbaum
Associate Professor of Clinical Pediatrics and Medicine, Columbia University's College of Physicians & Surgeons
-- Dr. Steven Shelov
Chairman of Pediatrics, Maimonides Medical Center
-- Dr. Maria K. Mitchell
President of AMDeC
-- Children and parents involved in the study
Academic Medicine Development Company (AMDeC)
amdec